Controlling multidrug-resistant tuberculosis and access to expensive drugs: a rational framework
- PMID: 12132008
- PMCID: PMC2567530
Controlling multidrug-resistant tuberculosis and access to expensive drugs: a rational framework
Abstract
The emergence and spread of multidrug-resistant tuberculosis (MDR-TB), i.e. involving resistance to at least isoniazid and rifampicin, could threaten the control of TB globally. Controversy has emerged about the best way of confronting MDR-TB in settings with very limited resources. In 1999, the World Health Organization (WHO) created a working group on DOTS-Plus, an initiative exploring the programmatic feasibility and cost-effectiveness of treating MDR-TB in low-income and middle-income countries, in order to consider the management of MDR-TB under programme conditions. The challenges of implementation have proved more daunting than those of access to second-line drugs, the prices of which are dropping. Using data from the WHO/International Union Against Tuberculosis and Lung Disease surveillance project, we have grouped countries according to the proportion of TB patients completing treatment successfully and the level of MDR-TB among previously untreated patients. The resulting matrix provides a reasonable framework for deciding whether to use second-line drugs in a national programme. Countries in which the treatment success rate, i.e. the proportion of new patients who complete the scheduled treatment, irrespective of whether bacteriological cure is documented, is below 70% should give the highest priority to introducing or improving DOTS, the five-point TB control strategy recommended by WHO and the International Union Against Tuberculosis and Lung Disease. A poorly functioning programme can create MDR-TB much faster than it can be treated, even if unlimited resources are available. There is no single prescription for controlling MDR-TB but the various tools available should be applied wisely. Firstly, good DOTS and infection control; then appropriate use of second-line drug treatment. The interval between the two depends on the local context and resources. As funds are allocated to treat MDR-TB, human and financial resources should be increased to expand DOTS worldwide.
Similar articles
-
[Development of antituberculous drugs: current status and future prospects].Kekkaku. 2006 Dec;81(12):753-74. Kekkaku. 2006. PMID: 17240921 Review. Japanese.
-
Management of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: current status and future prospects.Kekkaku. 2011 Jan;86(1):9-16. Kekkaku. 2011. PMID: 21401001
-
[Drug resistant tuberculosis].Pol Merkur Lekarski. 2011 May;30(179):362-6. Pol Merkur Lekarski. 2011. PMID: 21675144 Review. Polish.
-
Tuberculosis drug issues: prices, fixed-dose combination products and second-line drugs.Int J Tuberc Lung Dis. 2000 Dec;4(12 Suppl 2):S194-207. Int J Tuberc Lung Dis. 2000. PMID: 11144553 Review.
-
Multidrug-resistant tuberculosis (MDR-TB): epidemiology, prevention and treatment.Br Med Bull. 2005 Jun 14;73-74:17-24. doi: 10.1093/bmb/ldh047. Print 2005. Br Med Bull. 2005. PMID: 15956357 Review.
Cited by
-
Mycobacterium tuberculosis Essential Gene Thymidylate Synthase Is Involved in Immune Modulation and Survival inside the Host.ACS Omega. 2024 Jul 23;9(31):33743-33750. doi: 10.1021/acsomega.4c02919. eCollection 2024 Aug 6. ACS Omega. 2024. PMID: 39130601 Free PMC article.
-
Molecular modeling and dynamics studies of cytidylate kinase from Mycobacterium tuberculosis H37Rv.J Mol Model. 2008 May;14(5):427-34. doi: 10.1007/s00894-008-0291-2. Epub 2008 Mar 15. J Mol Model. 2008. PMID: 18343960
-
The domain architecture of PtkA, the first tyrosine kinase from Mycobacterium tuberculosis, differs from the conventional kinase architecture.J Biol Chem. 2018 Jul 27;293(30):11823-11836. doi: 10.1074/jbc.RA117.000120. Epub 2018 Jun 8. J Biol Chem. 2018. PMID: 29884774 Free PMC article.
-
[Antituberculosis-drug resistance in the border of Brazil with Paraguay and Bolivia].Rev Panam Salud Publica. 2017 Apr 20;41:e9. doi: 10.26633/RPSP.2017.9. Rev Panam Salud Publica. 2017. PMID: 28444009 Free PMC article. Portuguese.
-
Tuberculosis among homeless population from Medellín, Colombia: associated mental disorders and socio-demographic characteristics.J Immigr Minor Health. 2013 Aug;15(4):693-9. doi: 10.1007/s10903-013-9776-x. J Immigr Minor Health. 2013. PMID: 23340806
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials